Rae-GrantADayGSMarrieRAet al. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology2018; 90(17): 789–800.
2.
GiovannoniGTomicDBrightJRet al. “No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis. Mult Scler2017; 23(9): 1179–1187.
3.
RoccaMAAmatoMPDe StefanoNet al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol2015;14(3): 302–317.
4.
SumowskiJFBenedictREnzingerCet al. Cognition in multiple sclerosis: State of the field and priorities for the future. Neurology2018; 90(6): 278–288.
5.
ZipoliVGorettiBHakikiBet al. Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. Mult Scler2010; 16(1): 62–67.
6.
MocciaMLanzilloRPalladinoRet al. Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. Mult Scler2016; 22(5): 659–667.
7.
LangdonDWAmatoMPBoringaJet al. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler2012; 18: 891–898.
8.
BenedictRHDeLucaJPhillipsGet al. Multiple Sclerosis Outcome Assessments Consortium. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler2017; 23(5): 721–733.
Rae-GrantADayGSMarrieRAet al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology2018; 90(17):777–788.
